The TSP1-CD47-SIRPα interactome: an immune triangle for the checkpoint era Enrique MonteroJeffrey S. Isenberg Review Open access 22 May 2023 Pages: 2879 - 2888
A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma Hong-My NguyenMariam OladejoLaurence M. Wood Research 23 December 2022 Pages: 2889 - 2903
Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers Jordi Pfeifer SerrahimaCongcong ZhangWinfried S. Wels Research Open access 23 January 2023 Pages: 2905 - 2918
Therapeutic potential of FLT4-targeting peptide in acute myeloid leukemia Ji Yoon LeeSoojin ParkHee-Je Kim Research 10 February 2023 Pages: 2919 - 2925
Murine regulatory T cells utilize granzyme B to promote tumor metastasis Ellis TibbsRakhee Rathnam Kalari KandyXuefang Cao Research 24 February 2023 Pages: 2927 - 2937
A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model Joshua F. MecklerDaniel J. LevisJoseph M. Tuscano Research Open access 29 May 2023 Pages: 2939 - 2948
Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study Chengpei ZhuHu LiHaitao Zhao Research Open access 29 May 2023 Pages: 2949 - 2960
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study Matteo SantoniZin W. MyintCamillo Porta Research 29 May 2023 Pages: 2961 - 2970
Spatiotemporal commonality of the TCR repertoire in a T-cell memory murine model and in metastatic human colorectal cancer Mizuki HaraguchiKazuma KiyotaniRyohei Katayama Research 04 June 2023 Pages: 2971 - 2989
Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003) Yuankai ShiJie CuiWenduo He Research 08 June 2023 Pages: 2991 - 3002
NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model Hampartsoum B. BarsoumianKewen HeJames W. Welsh Research Open access 08 June 2023 Pages: 3003 - 3012
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer Colt A. EgelstonWeihua GuoYuan Yuan Research Open access 09 June 2023 Pages: 3013 - 3027
Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents Claire BattinAnnika De Sousa LinharesPeter Steinberger Research Open access 13 June 2023 Pages: 3029 - 3043
IL-36α inhibits melanoma by inducing pro-inflammatory polarization of macrophages Xinyi LouShixin DuanFeng Qian Research 15 June 2023 Pages: 3045 - 3061
Characterization of human Fc alpha receptor transgenic mice: comparison of CD89 expression and antibody-dependent tumor killing between mouse strains Marjolein C. StipJ. H. Marco JansenJeanette H. W. Leusen Research Open access 20 June 2023 Pages: 3063 - 3077
TGF-β1 mediates tumor immunosuppression aggravating at the late stage post-high-light-dose photodynamic therapy Lingfei HanXiaoxian HuangWenyuan Liu Research 23 June 2023 Pages: 3079 - 3095
The RIG-I agonist M8 triggers cell death and natural killer cell activation in human papillomavirus-associated cancer and potentiates cisplatin cytotoxicity Carlo GironeFederica CalatiMarisa Gariglio Research Open access 25 June 2023 Pages: 3097 - 3110
Unbiased chemokine receptor screening reveals similar efficacy of lymph node- and tumor-targeted T cell immunotherapy Ludwig O. PachmayrAnton MuehlbauerSimon Grassmann Brief Report Open access 10 June 2023 Pages: 3111 - 3124
Tumor immunology meets oncology (TIMO) XVI, July 07–09 2022 in Halle/Saale, Germany Barbara Seliger Meeting Report Open access 22 June 2023 Pages: 3125 - 3132
Considerations regarding the tumor-suppressor role of naringenin as a novel agent for the treatment of oral squamous cell carcinoma Chen-xi LiZhong-cheng GongXiao-rong Tan Correspondence 06 May 2023 Pages: 3133 - 3134